CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
P/B ratio for CVRx, Inc. (CVRX)
P/B ratio as of 2023: 8.59
According to CVRx, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.59. At the end of 2022 the company had a P/B ratio of 3.45.
P/B ratio history for CVRx, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 8.59 |
| 2022 | 3.45 |
| 2021 | 1.71 |
| 2020 | -1.84 |
| 2019 | -1.94 |